In platinum-treated, checkpoint inhibitor-naïve locally advanced or metastatic urothelial carcinoma (n=45), adding sacituzumab govitecan to atezolizumab did not improve confirmed response (6.7% vs 27.6% with atezolizumab alone), PFS or OS.
RCTn = 45
Shin et al. A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)